Fremanezumab Compassionate Use Program for Pediatric Patients

Summary

This is a Compassionate Use Program (CUP) based on a licensed physician's unsolicited request. Specifically, this CUP is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the Teva sponsored study TV48125-CNS-30084 (SPACE study).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications